Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

The approval is for follicular-lymphoma patients whose cancer has a mutation called EZH2 and who either failed to respond to treatment or whose cancer has recurred after therapy. The mutation ...

Their case report featured an 80-year-old woman receiving nivolumab for primary lung cancer who developed ... To help predict patients at higher risk for cutaneous immune-related adverse events ...

one of two T-cell engaging CD20xCD3 bispecific antibodies that Roche is developing along with mosunetuzumab which is being developed for follicular lymphoma (FL) and is closing in on approval in ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Feb. 29, 2024 — Keratin microsphere gel, consisting of keratin-based microspheres that swell in water to form a gel, has shown efficacy in promoting hair follicle growth in murine models.

A cyst can develop due to a clogged oil gland or hair follicle. Cysts feel like soft blisters when they are close to the skin’s surface, but they can feel like hard lumps when they develop ...